Search

Search

Home
...
Research Domains Biomedical and Clinical Sciences Oncology and Carcinogenesis Predictive and prognostic markers
Research Domains
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Predictive and prognostic markers
Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions?

Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions?

Georgios I Papageorgiou ¹, Nikolaos Skouteris ², Maria Grenzelia ³, Emmanouil Maragkoudakis ³, Kleopatra Eleftheriou ⁴

Georgios I Papageorgiou ¹, Nikolaos Skouteris ², Maria Grenzelia ³

¹2nd Medical Oncology Department, IASO General Clinic, Athens, Greece.
²3rd Medical Oncology Department, IASO General Clinic, Athens, Greece.
³Radiation Oncology Center, Iaso General Clinic, Marousi, Greece.
⁴Pharmacy Department, IASO General Clinic, Athens, Greece.

⁰2nd Medical Oncology Department, IASO General Clinic, Athens, Greece.

Immunotherapy +

|

March 21, 2025

|

March 21, 2025

Related Experiment Videos

Contact us if these videos are not relevant.

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

See all related videos

Summary

No abstract available on PubMed

Keywords:

Immunotherapy PD-L1 breast cancer liquid biopsy lung cancer treatment decisions urothelial cancer

Related Experiment Videos

Contact us if these videos are not relevant.

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

See all related videos

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Share

X
Facebook
LinkedIn
YouTube

ABOUT JoVE

Overview
Leadership
Blog
JoVE Help Center

AUTHORS

Publishing Process
Editorial Board
Scope & Policies
Peer Review
FAQ
Submit

LIBRARIANS

Testimonials
Subscriptions
Access
Resources
Library Advisory Board
FAQ

RESEARCH

JoVE Journal
Methods Collections
JoVE Encyclopedia of Experiments
Archive

EDUCATION

JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Faculty Resource Center
Faculty Site

Terms & Conditions of Use
Privacy Policy
Policies